Asthma Therapeutics in Asia-Pacific Market Analysis and Treatment, 2021: Hexa Reports

Hexa Reports

Market Research Reports and Insightful Company Profiles

Asthma Therapeutics in Asia-Pacific Market Size, Share,

Growth, Treatment, Analysis, Symptoms, Emerging Trends

and Opportunities to 2021

Asthma Therapeutics in Asia-Pacific Markets to 2021 - High Prevalence and Launch of Late-Stage

Biologics will Drive the Market in Spite of Affordability Concerns

Summary

Asthma is a common chronic inflammatory disease of the airways, characterized by recurrent attacks of

breathlessness and wheezing, which vary in frequency and severity from patient to patient. The exact

causes of asthma are currently unknown, and may be the result of a combination of factors, although

two major factors thought to be involved are environmental exposure and host factors, particularly

genes.

Browse Detail Report With TOC @

http://www.hexareports.com/report/asthma-therapeutics-in-asia-pacific-markets/details

Asthma treatment can be classed as either a long-term control medication, aimed at controlling

persistent asthma, or a quick-relief medication, for the relief of exacerbations and acute symptoms.

Long-term control medication includes Inhaled Corticosteroids (ICS), immunomodulators, leukotriene

modifiers, cromolyn sodium, nedocromil and methylxanthines.

Hexa Reports

Market Research Reports and Insightful Company Profiles

In addition, Long-Acting Beta-Adrenoceptor Agonists (LABAs) can be used in combination with ICSs

– but not as monotherapies – for moderate or severe persistent asthma. Currently, only

one biologic – Xolair (omalizumab) – is approved as an add-on therapy for the treatment

of allergic asthma in the Asia-Pacific region.  Nevertheless, significant unmet need remains for the

treatment of severe eosinophilic asthma.

Request A Sample copy of This Report @ http://www.hexareports.com/sample/105553

Scope

The current asthma market in the Asia-Pacific region contains novel products, including Xolair, a

recombinant humanized monoclonal anti-IgE...